For many years, the pharmaceutical business concentrated mostly on blockbuster medications, which are cures for common ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $40.0 and $60.0 for SpringWorks Therapeutics, spanning the last ...

Guggenheim lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $77 from $78 and keeps a Buy rating on the shares. The firm is ...

The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...

SpringWorks Therapeutics SWTX incurred a loss of $1.04 per share in the fourth quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 72 cents. The company had reported a ...

Reports FY24 revenue $191.5M, consensus $190.85M. “We are very pleased with the strong execution of OGSIVEO in 2024 and believe that we are ...

Shares of SWTX stock opened at $56.30 on Wednesday. SpringWorks Therapeutics has a 52 week low of $28.21 and a 52 week high of $60.00. The stock has a market capitalization of $4.19 billion ...

SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...

SpringWorks Therapeutics Inc (NASDAQ:SWTX) is set to release its Q4 2024 earnings on February 20, 2025. The consensus estimate for Q4 2024 revenue is $59.12 million, and the earnings are expected to ...

SPRINGWORKS THERAPEUTICS ($SWTX) posted quarterly earnings results on Thursday, February 20th. The company reported earnings of -$1.04 per share, missing estimates of ...